Sign in Create account

Rossari Biotech Limited

Chemicals · Chemicals & Petrochemicals

NSE: ROSSARI BSE: 543213
₹417.95
▼ -9.75 (-2.28%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
68/100
Moderate
Valuation
88/100
Undervalued
Momentum
9/100
Bearish

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Rossari Biotech is an Indian chemical manufacturing company with a focus on specialty chemicals. It is also engaged in production of specialty enzymes and chemicals in India that is used in the pharmaceuticals, paper, construction, textiles, nutrition and animal health industries. The company was started in 2003 as a partnership firm titled Rossari Labtech and was incorporated into a company in 2009 and was renamed as Rossari Biotech.

Source: Wikipedia

Key Metrics

Market Capitalization
₹2,315 Cr
PE (TTM)
15.3
Industry median 24.4 (189 companies)
Price to Book
1.7
PEG (TTM)
0.5
Institutions holding %
16.66%
FII + DII, latest filed period
Piotroski Score
4
Relative return vs Nifty50, qtr %
-12.0
Relative return vs Sector, qtr %
-18.6
Free Cash Flow
₹-200 Cr
as of March 31, 2026
Industry median ₹-0 Cr (238 companies)
EPS Growth (YoY)
30.59%
as of June 30, 2026
Industry median 39.08% (220 companies)
Net Profit Growth (TTM)
29.34%
as of June 30, 2026
Industry median 13.45% (212 companies)
Operating Revenue Growth (TTM)
24.85%
as of June 30, 2026
Industry median 7.93% (209 companies)
Profit Growth (YoY)
30.62%
as of June 30, 2026
Industry median 23.11% (213 companies)
Revenue Growth (YoY)
31.86%
as of June 30, 2026
Industry median 17.49% (205 companies)
Current Ratio
1.57
as of March 31, 2026
Industry median 1.87 (237 companies)
Debt to Equity
0.31
as of March 31, 2026
Industry median 0.16 (224 companies)
Interest Coverage
15.33
as of June 30, 2026
Industry median 8.97 (221 companies)
Net Margin
7.11%
as of June 30, 2026
Industry median 7.49% (212 companies)
Operating Margin (EBIT)
10.42%
as of June 30, 2026
Industry median 11.88% (214 companies)
Operating Margin (TTM)
11.57%
as of June 30, 2026
Industry median 9.75% (219 companies)
Return on Assets
6.41%
as of March 31, 2026
Industry median 4.33% (217 companies)
Return on Capital Employed
15.14%
as of March 31, 2026
Industry median 10.34% (218 companies)
Return on Equity
11.01%
as of March 31, 2026
Industry median 7.52% (219 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 4)
  • Yes Debt to equity is below 0.5 (0.31)
  • No Return on equity is 15% or more (11.0%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 4 met
  • No FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.3%
Low 416.0000 · High 434.6000
1W return
-8.1%
Low 416.0000 · High 451.4000
1M return
-13.9%
Low 416.0000 · High 488.9500
52W return
-34.3%
Low 375.0000 · High 690.3000
Lifetime High ₹1571.5000 (Oct. 11, 2021)
Lifetime Low ₹378.6000 (March 30, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
431.6
10D
438.1
20D
448.9
50D
472.1
100D
489.2
200D
505.2

Delivery and volume

Day avg. delivery
38.9%
Week avg. delivery
54.4%
Month avg. delivery
53.3%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

422.85
Pivot
First resistance429.70
Second resistance441.45
Third resistance448.30
First support411.10
Second support404.25
Third support392.50
Day RSI25.8
Day MFI26.6
Day MACD-14.63
Day MACD signal-14.31

Beta

1M1.09
3M1.28
1Y1.21
3Y0.83

Price change analysis

↓ -13.9%
Over 1 Month
LowHigh
416.00488.95
↓ -20.7%
Over 3 Months
LowHigh
416.00549.00
↑ 3.4%
Over 6 Months
LowHigh
392.55575.00
↓ -34.3%
Over 1 Year
LowHigh
375.00690.30
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 15.3 (own history: 14.7–48.5)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹482 Cr
Net profit (June 30, 2026)
₹34 Cr
Basic EPS (June 30, 2026)
₹6.1900

Ranks #57 of 221 in Chemicals & Petrochemicals by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter68.14%
  • Mutual funds9.77%
  • FII/FPI2.02%
  • Other DII4.87%
  • Public15.20%

Largest holders

NameCategoryShares %Shares
Edward MenezesPromoter29.1000%16118820
Sunil Srinivasan ChariPromoter13.1600%7289320
Chari Family Trust in the name of Sunil Srinivasan Chari and Jyotishna Sunil ChariPromoter9.2300%5110000
Uti-Flexi Cap FundPublic6.3600%3522645
Rossari Biotech India Private LimitedPromoter5.4500%3016200

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 68.15% to 68.14% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 2.18% to 2.02% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 13.38% to 9.77% in Jun 2026 qtr

2 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 60 insider trades, 7 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
29 Aug 2025 Chari Family Trust - in the name of Sunil Srinivasan Chari & Jyotishna Sunil Chari Promoter group Buy 0 ₹0
29 Aug 2025 Jyotishna Sunil Chari Promoter group Buy 0 ₹0
29 Aug 2025 Sunil Srinivasan Chari Promoter Sell 0 ₹0
29 Aug 2025 Yash Suni Chari Promoter group Buy 0 ₹0
1 Sep 2021 Jose Abraham Other Pledge Revoke 0 ₹8.20 L
1 Sep 2021 Sudhir Sawant Other Pledge Revoke 0 ₹6.88 L
1 Sep 2021 Shantanu Dey Other Pledge Revoke 0 ₹1.37 L
13 Aug 2021 Manasi Nisal Other Pledge Revoke 0 ₹17.55 L
13 Aug 2021 Sandeep Shanbhag Other Pledge Revoke 0 ₹5.47 L
13 Aug 2021 Manjiri Paranjape Other Pledge Invoke 0 ₹13.57 L

All insider and SAST disclosures →

Deals (Bulk & Block)

All 45 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
30 Apr 2026 BHUPESH KUMAR LODHA Bulk Buy 298,000 491.5000 NSE
20 Sep 2021 GOLDMAN SACHS INDIA FUND LIMITED Block Sell 666,135 1478.6500 BSE
20 Sep 2021 GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIO Block Buy 666,135 1478.6500 BSE
20 Sep 2021 GOLDMAN SACHS INDIA FUND LIMITED Bulk Sell 666,135 1478.6500 BSE
20 Sep 2021 GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIO Bulk Buy 666,135 1478.6500 BSE
19 Jul 2021 PUBLIC SECTOR PENSION INVESTMENT BOARD Block Buy 166,875 1249.5000 NSE
19 Jul 2021 IIFL SPECIAL OPPORTUNITIES FUND SERIES 4 Block Sell 166,875 1249.5000 NSE
19 Jul 2021 PUBLIC SECTOR PENSION INVESTMENT BOARD Block Buy 166,875 1249.5000 NSE
19 Jul 2021 IIFL SPECIAL OPPORTUNITIES FUND SERIES 4 Block Sell 166,875 1249.5000 NSE
2 Sep 2020 PLUTUS WEALTH MANAGEMENT LLP Bulk Buy 300,000 773.8200 NSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹0.50 per share
Dividend yield 0.12%
Ex-dateSubjectPer share (₹)Record date
10 Jul 2026 Dividend - Rs 0.50 Per Share 0.5000 10 Jul 2026
20 Jun 2025 Dividend - Re 0.50 Per Share 0.5000 20 Jun 2025
16 Aug 2024 Annual General Meeting/Dividend - Re 0.50 Per Share 0.5000 —
24 May 2023 Annual General Meeting/Dividend - Re 0.50 Per Share 0.5000 —
7 Jul 2022 Annual General Meeting/Dividend - Rs 0.50 Per Share 0.5000 —
8 Sep 2021 Annual General Meeting/Dividend - Rs 0.50 Per Share 0.5000 —

Corporate Actions

Full history (7 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
4 Nov 2024OTHERExtra Ordinary General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
18 Jul 2026 Financial Results Yes
27 Apr 2026 Financial Results/Dividend Yes
17 Jan 2026 Financial Results Yes
15 Oct 2025 Financial Results Yes
19 Jul 2025 Financial Results Yes

Corporate Announcements

All 522 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Trading Window Rossari Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Insider Trading / SAST Rossari Biotech Ltd - 543213 - Closure of Trading Window
16 Sep 2026 Company Update Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
10 Sep 2026 Company Update Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
6 Aug 2026 Updates Intimation of non-participation in the investors and analysts meet scheduled on Monday, August 10, 2026.
3 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
24 Jul 2026 Analysts/Institutional Investor Meet/Con. Call Updates Intimation of Transcript of Q1 FY 27 for the Earnings Conference Call held on July 20, 2026.
20 Jul 2026 Shareholders meeting Outcome of 17th Annual General Meeting of the Members of the Company along with Proceedings, Voting Results and Scrutinizers Report.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Comfortable interest coverage (15.3x)
  • Healthy liquidity (Current Ratio 1.57)
  • Strong revenue growth YoY (31.9%)

Weaknesses

Data unavailable.

Opportunities

  • PEG below 1 (0.53) -- earnings growth outpacing its own valuation
  • RSI in oversold territory (25.8) -- a technical rebound zone

Threats

  • Down 34.3% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Rossari Biotech Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.